Formulation and Evaluation of Orodispersible Tablet of Sulindac

Bhavna B. Gaikwad, Bhushan R. Rane and Ashish S. Jain
Additional contact information
Bhavna B. Gaikwad: Shri D. D. Vispute College of Pharmacy & Research Center Panvel, India
Bhushan R. Rane: Shri D. D. Vispute College of Pharmacy & Research Center Panvel, India
Ashish S. Jain: Shri D. D. Vispute College of Pharmacy & Research Center Panvel, India

European Journal of Pharmaceutical Research, 2022, vol. 2, issue 3, 11-19

Abstract: Oral administration of dosage form is the most recommended mode of administration, because of its self-medication, accurate dose of the drug, and ease of administration. However, trouble swallowing in geriatric patients is one major negative of this route, which can mentally disrupt patients. The goal of this study was to use the direct compression method to make orodispersible tablets of sulindac utilizing various doses of super disintegrant agents such as Sodium starch glycolate Crospovidone and Croscarmellose sodium. Three distinct super disintegrants were used to create nine formulations with varying concentration levels. The preformulation, precompression, and post-compression properties of the powder combinations were assessed. In comparison to the other formulations, tablets from batch F3 containing crospovidone had superior organoleptic qualities, as well as outstanding drug release and in-vitro disintegration time. The super disntegrants addition technique was shown to be a viable method for manufacturing orodispersible tablets using the direct compression method.

Keywords: Croscarmellose sodium; crospovidone; direct compression method; orodispersible tablets (ODTs); sodium starch glycolate; sulindac (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
https://eu-opensci.org/index.php/pharma/article/view/741 Abstract page (text/html)
https://eu-opensci.org/index.php/pharma/article/download/741/307 Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:epw:pharma:v:2:y:2022:i:3:id:741

DOI: 10.24018/ejpharma.2022.2.3.41

Access Statistics for this article

More articles in European Journal of Pharmaceutical Research from European Open Science Publishing
Bibliographic data for series maintained by Support Team ().